Pharma Mar SAU

Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology. It operates in Spain, Germany, Ireland, France, Switzerland, the rest of the European Union, the United States, and internationally, through Oncology and RNA Interference segments. Its products include Yondelis for soft tissue sarcoma and ovarian cancer, Zepzelca for small cell lung cancer, and Aplidin for multiple myeloma. The company is also developing LAGOON, SaLuDo, PM534, PM54, and SYL1801 in various clinical trial phases. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.